David A. Siegel Scynexis Inc Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.77 - $3.87 $26,019 - $56,889	-14,700 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.56 - $6.66 $188,181 - $352,047	-52,860 Reduced 78.24%	14,700 $57,000
Q4 2021 Feb 14, 2022	SELL	$4.94 - $7.69 $851,013 - $1.32 Million	-172,270 Reduced 71.83%	67,560 $412,000
Q3 2021 Nov 15, 2021	SELL	$5.3 - $7.89 $800,830 - $1.19 Million	-151,100 Reduced 38.65%	239,830 $1.27 Million
Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $151,450 - $232,301	23,300 Added 6.34%	390,930 $2.88 Million
Q1 2021 May 17, 2021	BUY	$6.93 - $9.63 $2.55 Million - $3.54 Million	367,630 New	367,630 $2.92 Million

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.